Market: NASD |
Currency: USD
Address: 910 Clopper Road
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
📈 Altimmune, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$18.44
-
Upside/Downside from Analyst Target:
421.03%
-
Broker Call:
14
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
10-25%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2025-11-11
-
EPS Estimate:
-0.27
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2018 |
- |
$0.033333 |
- |
2018-09-14 |
- |
Stock split |
|
Total Amount for 2018: $0.033333 |
📅 Earnings & EPS History for Altimmune, Inc.
| Date | Reported EPS |
|---|
| 2025-11-11 (estimated upcoming) | - |
| 2025-08-12 | -0.27 |
| 2025-05-13 | -0.26 |
| 2025-02-27 | -0.33 |
| 2024-11-12 | -0.32 |
| 2024-08-08 | -0.35 |
| 2024-05-09 | -0.34 |
| 2024-03-27 | -0.33 |
| 2023-11-07 | -0.39 |
| 2023-08-10 | -0.32 |
| 2023-05-11 | -0.4 |
| 2023-02-28 | -0.44 |
| 2022-11-10 | -0.48 |
| 2022-08-11 | -0.42 |
| 2022-05-12 | -0.44 |
| 2022-03-15 | -0.49 |
| 2021-11-09 | -0.81 |
| 2021-08-10 | -0.6 |
| 2021-05-17 | -0.38 |
| 2021-02-25 | -0.17 |
| 2020-11-09 | -0.54 |
| 2020-08-11 | -0.94 |
| 2020-05-13 | -0.26 |
| 2020-03-27 | -0.25 |
| 2019-11-13 | -0.19 |
📰 Related News & Research
No related articles found for "altimmune inc".
